We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pediatric considerations for pharmacogenetic selective serotonin reuptake inhibitors clinical decision support.
- Authors
Liu, Michelle; Rossow, Katelyn M.; Maxwell‐Horn, Angela C.; Saucier, Leigh Ann; Van Driest, Sara L.
- Abstract
Pharmacogenetic testing for psychiatry is growing at a rapid pace, with multiple sites utilizing results to help clinical decision‐making. Genotype‐guided dosing and drug selection have been implemented at several sites, including Vanderbilt University Medical Center, where clinical decision support (CDS) based on pharmacogenetic results went live for selective serotonin reuptake inhibitors in 2020 for both adult and pediatric patients. Effective and appropriate implementation of CYP2D6‐ and CYP2C19‐guided CDS for the pediatric population requires consideration of the evidence for the pharmacogenetic associations, medication indications, and appropriate alternative therapies to be used when a pharmacogenetic contraindication is identified. In this article, we review these pediatric pharmacogenetic considerations for selective serotonin reuptake inhibitor CDS. We include a case study, the current literature supporting clinical recommendations, considerations when designing pediatric CDS, future implications, and examples of sertraline, (es)citalopram, paroxetine, and fluvoxamine alerts.
- Subjects
VANDERBILT University. Medical Center; CLINICAL decision support systems; SEROTONIN uptake inhibitors; ANTIDEPRESSANTS; CHILD patients; ACADEMIC medical centers
- Publication
Pharmacotherapy, 2023, Vol 43, Issue 7, p691
- ISSN
0277-0008
- Publication type
Article
- DOI
10.1002/phar.2751